 LEXINGTON, Mass., Dec. 7, 2020 PRNewswire -- Curis, Inc. NASDAQ: CRIS, a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated data from its ongoing Phase 1, open-label, dose escalation study of CA-4948, an... 